WILMINGTON, Del., March 5, 2015 /PRNewswire/ -- Rigrodsky &
Long, P.A.:
- Do you own shares of Pharmacyclics, Inc. (NASDAQ GS:
PCYC)?
- Did you purchase any of your shares prior to March 5, 2015?
- Do you think the proposed buyout value is too low?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating
potential legal claims against the board of directors of
Pharmacyclics, Inc. ("Pharmacyclics" or the "Company") (NASDAQ GS:
PCYC) regarding possible breaches of fiduciary duties and other
violations of law related to the Company's entry into an agreement
to be acquired by AbbVie Inc. ("AbbVie") (NYSE: ABBV), in a
transaction valued at approximately $21
billion.
Click here to learn more:
http://www.rigrodskylong.com/investigations/pharmacyclics-inc-pcyc.
Under the terms of the agreement, shareholders of Pharmacyclics
will receive $261.25 per share,
consisting of cash and AbbVie common stock. Pharmacyclics'
stockholders will be permitted to elect cash, AbbVie common stock
or a combination, subject to proration. The aggregate
consideration will consist of approximately 58% cash and 42% AbbVie
common stock.
The investigation concerns whether Pharmacyclics' board of
directors failed to adequately shop the Company and obtain the best
possible value for Pharmacyclics' shareholders before entering into
an agreement with AbbVie.
If you own the common stock of Pharmacyclics and purchased your
shares before March 5, 2015, if you
have information or would like to learn more about these claims, or
if you wish to discuss these matters or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2
Righter Parkway, Suite 120, Wilmington,
DE 19803, by telephone at (888) 969-4242; by e-mail to
info@rl-legal.com, or at:
http://www.rigrodskylong.com/investigations/pharmacyclics-inc-pcyc.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes
securities class, derivative and direct actions, shareholder rights
litigation and corporate governance litigation, on behalf of
shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a
similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pharmacyclics-inc-shareholder-alert-rigrodsky--long-pa-announces-investigation-of-buyout-300046482.html
SOURCE Rigrodsky & Long, P.A.